Axitinib: in advanced, treatment-experienced renal cell carcinoma.
about
VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patientsIncidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.
P2860
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@en
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@nl
type
label
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@en
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@nl
prefLabel
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@en
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@nl
P2860
P1433
P1476
Axitinib: in advanced, treatment-experienced renal cell carcinoma.
@en
P2093
Kate McKeage
P2860
P304
P356
10.2165/11209230-000000000-00000
P577
2012-12-01T00:00:00Z
P6179
1046527063